Mark R. Brann

ENABLING METHODS TO IDENTIFY ALLOSTERIC MODULATORS OF RECEPTOR ACTIVITY

IDENTIFICATION OF LIGANDS BY SELECTIVE AMPLIFICATION OF CELLS TRANSFECTED WITH RECEPTORS

Selective serotonin receptor inverse agonists as therapeutics for disease

Clinical indications for genotyping polymorphic variants of G-protein coupled receptors

Identification of 5HT2A receptor ligands by selective amplification of cells transfected with receptors

Identification of ligands by selective amplification of cells transfected with receptors

Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

Use of N-desmethylclozapine to treat human neuropsychia tric disease

Use of N-desmethylclozapine to treat human neuropsychiatric disease

Selective serotonin receptor inverse agonists as therapeutics for disease

Selective serotonin receptor inverse agonists as therapeutics for disease

Selective serotonin receptor inverse agonists as therapeutics for disease

Use of N-desmethylclozapine to treat human neuropsychiatric disease

Identification of ligands by selective amplification of cells transfected with a 5HT2A receptor

Methods of identifying inverse agonists of the serotonin 2A receptor

Use of N-desmethylclozapine to treat human neuropsychiatric disease